c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity

The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells

(2011) Pablo E. Morande et al.   INVESTIGATIONAL NEW DRUGS

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma

(2010) M. V. Mateos et al.   CLINICAL CANCER RESEARCH

Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling

(2008) Atsushi Matsuzawa et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma

(2008) J Caers et al.   BRITISH JOURNAL OF CANCER

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor

(2008) Feng (Roger) Luo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

(2008) C. S. Mitsiades et al.   CANCER RESEARCH

JNK signaling in apoptosis

(2008) D N Dhanasekaran et al.   ONCOGENE